Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Other Operating Expenses (2023 - 2025)

Immunome (IMNM) has disclosed Other Operating Expenses for 3 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 63.47% year-over-year to $10.0 million, compared with a TTM value of $10.0 million through Dec 2025, down 93.44%, and an annual FY2025 reading of $10.0 million, down 93.44% over the prior year.
  • Other Operating Expenses was $10.0 million for Q4 2025 at Immunome, down from $27.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $112.0 million in Q1 2024 and bottomed at $6.3 million in Q2 2024.
  • Average Other Operating Expenses over 3 years is $40.5 million, with a median of $18.7 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses tumbled 66.12% in 2024, then plummeted 63.47% in 2025.
  • Year by year, Other Operating Expenses stood at $80.8 million in 2023, then crashed by 66.12% to $27.4 million in 2024, then tumbled by 63.47% to $10.0 million in 2025.
  • Business Quant data shows Other Operating Expenses for IMNM at $10.0 million in Q4 2025, $27.4 million in Q4 2024, and $6.7 million in Q3 2024.